Phreesia (PHR) Set to Announce Earnings on Monday

Phreesia (NYSE:PHR) is scheduled to be releasing its earnings data after the market closes on Monday, December 9th. Analysts expect Phreesia to post earnings of ($0.29) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Phreesia (NYSE:PHR) last announced its quarterly earnings data on Wednesday, September 4th. The company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.06. Phreesia had a negative return on equity of 39.34% and a negative net margin of 25.73%. The firm had revenue of $102.12 million during the quarter, compared to analysts’ expectations of $101.76 million. On average, analysts expect Phreesia to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Phreesia Price Performance

Shares of NYSE:PHR opened at $21.73 on Friday. Phreesia has a twelve month low of $17.07 and a twelve month high of $29.16. The stock’s 50 day moving average is $20.28 and its 200-day moving average is $21.76. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of -12.07 and a beta of 0.98.

Insider Activity at Phreesia

In related news, insider Yvonne Hui sold 2,791 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $20.92, for a total value of $58,387.72. Following the transaction, the insider now directly owns 27,228 shares in the company, valued at approximately $569,609.76. This represents a 9.30 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Chaim Indig sold 5,295 shares of Phreesia stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $23.25, for a total transaction of $123,108.75. Following the sale, the chief executive officer now owns 1,223,736 shares of the company’s stock, valued at approximately $28,451,862. The trade was a 0.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 70,596 shares of company stock valued at $1,518,892. Corporate insiders own 5.80% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on PHR. Canaccord Genuity Group restated a “buy” rating and set a $34.00 price objective on shares of Phreesia in a research note on Thursday, September 5th. Royal Bank of Canada restated a “sector perform” rating and set a $23.00 price target on shares of Phreesia in a report on Friday, September 27th. JPMorgan Chase & Co. increased their price objective on shares of Phreesia from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Monday, September 9th. Robert W. Baird boosted their target price on Phreesia from $31.00 to $34.00 and gave the stock an “outperform” rating in a research note on Friday, September 6th. Finally, Truist Financial increased their price target on Phreesia from $29.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, September 6th. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Phreesia currently has a consensus rating of “Moderate Buy” and an average target price of $29.42.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.